Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 10/20 | 0.57 |
| ▸ | WNT3A | P56704 | 10/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013031 | 1.00 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAAPTPN1 | |
| SCHEMBL30089582 | 0.84 | CTNNB1 (0.75) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL5358010 | 0.84 | PTPN1 (0.46) | CTNNB1WNT3ALMNAGAAPTPN1 | |
| SCHEMBL1198865 | 0.84 | CTSS (0.48) | CTNNB1WNT3ALMNAGAAPTPN1 | |
| SCHEMBL2073272 | 0.82 | CTNNB1 (0.58) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL19858887 | 0.82 | CTNNB1 (0.58) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL9526234 | 0.82 | CTSS (0.49) | PTPN1GSK3B | |
| SCHEMBL2092338 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL8232789 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL5367757 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752438-A2 | Process for preparation of optionally substituted trifluoromethyl phenacyl bromide | Saltigo GmbH (DE) | 2007-02-14 | — | — | EP | claimed |
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-115246826-B | Quaternary ammonium salt isoxazoline compound, its preparation and application as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-0509974-B1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | ASTRA AB (SE) | 1999-01-13 | — | — | EP | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| CN-1067892-A | The preparation method of new pyrrolo-[2,3-b] pyridine derivate | ASTRA AB (SE) | 1993-01-13 | — | — | CN | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
| US-3965181-A | Tricyclic pharmacological agents, intermediates and methods of making | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | CTNNB1 1806/4885WNT3A 2237/4885LMNA 715/4885 |
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | CTNNB1 1999/4885WNT3A 3446/4885LMNA 3667/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | CTNNB1 577/4885WNT3A 403/4885LMNA 3592/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | CTNNB1 427/4885WNT3A 362/4885LMNA 3739/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | CTNNB1 1806/4885WNT3A 2237/4885LMNA 715/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | CTNNB1 4082/4885WNT3A 4135/4885LMNA 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.